Vaccines and Related Biological Products Advisory Committee reviewed data from the biologics license application for RBX2660 RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment Recurrent C. difficile infection represents a significant burden for patients, caregivers, and the healthcare system Saint-Prex, Switzerland and Parsippany, NJ, USA – September […]

Ferring to share insights and expertise across a range of timely and critical topics at the Women’s Health Innovation Summit in Boston As the headline sponsor, Ferring will have a significant presence with executives providing the keynote address, participating on several panels and hosting an Innovation Council Parsippany, NJ, USA – September 15, 2022 – Ferring Pharmaceuticals will join industry experts, […]

Vaccines and Related Biological Products Advisory Committee will hold meeting on September 22, 2022 RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection after antibiotic treatment Saint-Prex, Switzerland and Parsippany, NJ, USA – August 9, 2022 – Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of […]